Delivery Order 36F79723D0136-36C26024F0092
Award Date
1/1/24
Potential Completion Date
3/31/24
Potential Value
$110K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Amylyx Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
East Cambridge, MA 02141, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amylyx Pharmaceuticals Inc., doing business as Amylyx, is for the delivery of RELYVRIO Sodium, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS). The $42,334.56 firm-fixed-price delivery order was issued by the Veterans Integrated Service Network 21 (VISN 21), a division of the Department of Veterans Affairs (VA).
The contract has no set-aside designation and is intended to supply RELYVRIO to VA medical facilities in the western United States....
Amylyx Pharmaceuticals Inc. was awarded a $46,799.80 firm fixed price delivery order by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 to provide its amyotrophic lateral sclerosis drug RELYVRIO. The order, issued without a set-aside designation, has a period of performance through May 1, 2024 for delivery to a location in Cambridge, Massachusetts. Amylyx holds several federal vehicles that facilitate provision of its pharmaceutical...
This is a firm-fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Amylyx Pharmaceuticals Inc., a self-certified small disadvantaged business. The contract, valued at $10,530.00, is for the provision of RELYVRIO, an FDA-approved treatment for amyotrophic lateral sclerosis (ALS), to the Puget Sound VA Medical Center. The contract has an ultimate completion date of December 21, 2023.
Amylyx Pharmaceuticals holds several significant indefinite delivery...
This is a federal delivery order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Amylyx Pharmaceuticals Inc. (Amylyx), a small disadvantaged business. The $250,414.72 firm fixed price contract is for the delivery of RELYVRIO, Amylyx's pharmaceutical product containing sodium phenylbutyrate and taurursodiol, which is indicated for the treatment of amyotrophic lateral sclerosis (ALS). This delivery order was placed against larger...
This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs Veterans Health Administration to Anovorx Distribution LLC, a small business for-profit limited liability company, to provide the medication Firdapse (Amifampridine). The contract has a potential value of $151,359.02 and a completion date of September 19, 2019. Anovorx Distribution LLC has provided various specialty pharmaceutical products to the VA and Department of the Army Medical Command...
This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date...
The U.S. Department of Veterans Affairs (VA) awarded a firm fixed-price delivery order contract to Acorda Therapeutics, Inc., a biotechnology company specializing in therapies for neurological disorders. The contract, valued at $478,860.00, is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease and multiple sclerosis. The delivery order was placed under Acorda's existing Federal Supply Schedule (FSS) contract with the VA (36F79723D0194), valued at over $16.3...
This federal contract award, valued at $95,772.00, was issued by the Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies. The contract is a delivery order under Acorda's Federal Supply Schedule (FSS) contract with the VA, which has a total value of over $16.3 million and is used to procure the company's pharmaceutical products, including Levodopa 42mg inhalation capsules for the treatment of Parkinson's disease. The...
This federal contract award, valued at $43,476.60, was issued by the Department of Veterans Affairs (VA) to Biogen U.S. Corporation, a pharmaceutical and biotechnology company. The contract is a firm-fixed-price delivery order placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract.
The contract is for the delivery of QALSODY (tofersen), a pharmaceutical product used to treat neurological conditions in veterans. This award does not carry a...
This federal contract award was made by the Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological disorders. The contract is for the delivery of DALFAMPRIDINE, which is likely a medication used to treat Parkinson's disease and multiple sclerosis. The contract was awarded as a Firm Fixed Price Delivery Order under Acorda's Federal Supply Schedule (FSS) contract with the VA, valued at over $16.3 million. The contract has a ceiling...